Latest:
Dr Vivekanandarajah on Identifying HER2-Mutated NSCLC in the Community Setting
Abhirami Vivekanandarajah, MD, shares how she tests and treats patients with HER2-mutated non–small cell lung cancer in the community setting.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Henry S. Park, MD, MPH
Latest:
Dr Park on the Role of Radiation Therapy in NSCLC
Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.
Doris M. Ponce, MD
Latest:
Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Adam Kittai, MD
Latest:
Dr Kittai on an Indirect Comparison of Acalabrutinib Plus Obinutuzumab vs Zanubrutinib in CLL/SLL
Adam Kittai, MD, discusses key findings from a matching-adjusted, indirect comparison of acalabrutinib with or without obinutuzumab vs zanubrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
George Lau, MD, FRCP, FAASLD
Latest:
Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC
George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.
Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center
Latest:
Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer
Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.
David O’Malley, MD
Latest:
Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC
Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.
Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center
Latest:
MRD Testing and the Role of Revumenib in Treatment Response
Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.